Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Merz

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA accelerated approval for solid tumours

The ADC has been authorised to treat adults with unresectable or metastatic HER2-positive tumours

Daiichi Sankyo logo

Daiichi Sankyo’s Vanflyta approved by MHRA to treat acute myeloid leukaemia

The blood cancer affects approximately 3,100 people in the UK annually

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu not recommended by NICE for advanced breast cancer

Breast cancer is the most common form of cancer in the UK, accounting for over 55,000 cases every year

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced lung cancer

Non-small cell lung cancer accounts for approximately 85% of all lung cancer cases

- PMLiVE

Merck and Daiichi Sankyo announce ADC agreement worth up to $22bn

The companies will jointly develop and commercialise three of Daiichi Sankyo’s cancer candidates

- PMLiVE

Life sciences leaders warn against ‘unworkable’ changes to UK medicines scheme

The scheme could impact UK life sciences and NHS patient access to medicines

- PMLiVE

AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study

More than two million people worldwide are diagnosed with breast cancer every year

- PMLiVE

Health and Social Care Committee report on vaccination calls for urgent action in the UK

In England, coverage for childhood immunisations was below target in 2021 and 2022

- PMLiVE

UK life sciences sector sees substantial drop in international investment

The estimated value of inward foreign direct investment fell from £1.9bn in 2021 to £1bn in 2022

- PMLiVE

AstraZeneca and Daiichi Sankyo share positive results from phase 3 lung cancer study

The investigational drug met the dual primary endpoint of progression-free survival

- PMLiVE

MHRA to introduce new UK clinical trials framework

The changes will aim to make it easier to gain approval and to run clinical trials in the UK

- PMLiVE

ABPI welcomes new NHS research guidance for integrated care systems

Included in the proposals are calls for a fixed rebate rate of 6.88% on all eligible NHS medicine sales to be paid by the industry

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links